Filing Flows › Precision Biosciences (DTIL) › Q3 FY25
Precision Biosciences (DTIL) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed May 15, 2025
Precision Biosciences (DTIL) reported revenue of $29K for the third quarter fiscal 2025 (Q3 FY25), -100% from a year earlier and -95% from the quarter before.
Precision Biosciences, Q3 FY25: revenue $29K (-100% year over year), net loss $20.6M, operating cash flow −$19.1M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29K | -95% | -100% |
| Operating profit | −$22.1M | — | — |
| Net earnings | −$20.6M | — | — |
| Operating cash flow | −$19.1M | — | — |
What changed
Revenue was $29K in Q3 FY25, down 100% year over year and down 95% from the previous quarter.
Operating costs exceeded revenue by $22.1M, an operating margin of -76248.3%. Total costs grew 2% against a revenue fall of 100%. The quarter ended with a net loss of $20.6M, wider than the previous quarter's $17.7M loss.
Operating cash flow was −$19.1M. Non-cash charges added back $395K of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items used $1.7M. Capital expenditures of $64K exceeded it, leaving free cash flow of −$19.1M.
Questions
What was Precision Biosciences' revenue in the third quarter fiscal 2025?
Precision Biosciences (DTIL) reported revenue of $29K for the third quarter fiscal 2025 (Q3 FY25), -100% from a year earlier and -95% from the quarter before.